Rationale and design of European microCirculatory Resistance and Absolute Flow Team: The Euro-CRAFT Registry.

Introduction: Coronary microvascular dysfunction (CMD) is increasingly recognized as an important cause of anginal symptoms and poor outcomes. Angina with non-obstructive coronary arteries (ANOCA) is often related to CMD. While physiological assessment of microcirculatory function by coronary bolus thermodilution is widely practiced, more precise and reproducible methodology as well as systematic assessment are necessary.

Gene therapy in cardiac and vascular diseases: a review of approaches to treat genetic and common cardiovascular diseases with novel gene-based therapeutics.

In the past decade, there has been substantive progress in gene therapy across disease indications. However, despite multiple gene therapies being approved for clinical use, none have a cardiovascular indication. Several reasons for this have inhibited or delayed progress in the cardiovascular field.

Associations and Prognostic Implications of Myocardial Tissue Injury Stages in ST-Elevation Myocardial Infarction Using the Canadian Cardiovascular Society Classification.

Aims: The recently proposed Canadian Cardiovascular Society (CCS) classification categorizes post-infarction tissue injury into four stages, potentially improving risk stratification and guiding cardioprotective strategies. Its clinical and prognostic relevance in ST-elevation myocardial infarction (STEMI) remains unclear. We aimed to compare clinical characteristics across CCS stages and validate their prognostic implications in STEMI.

Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial.

Background And Aims: Invasive coronary function testing (CFT) identifies coronary vasomotor disorders in up to 90% of patients with angina with non-obstructive coronary arteries (ANOCA). The ILIAS ANOCA trial hypothesized that routine ad hoc CFT would be feasible, safe, and effective in providing an early, comprehensive diagnosis. Additionally, it was anticipated that combining CFT with a disease-specific treatment protocol would significantly improve quality of life in ANOCA patients compared with standard care.

Latent Cytomegalovirus Infection Is Associated With Impaired Left Ventricular Function After ST-Segment-Elevation Myocardial Infarction.

Background: Human cytomegalovirus is a herpes virus that affects most individuals globally and may increase the risk of cardiovascular disease. Whether cytomegalovirus influences outcomes after ST-segment-elevation myocardial infarction (STEMI) is unknown. Our objective was to investigate the association between latent cytomegalovirus infection and outcomes after STEMI.

Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects.

Recognition of benefits and adverse effects of therapies in earlier clinical trial phases could improve the safety, efficiency, and cost of clinical trials. Using four clinical trials representing a diverse set of diseases and drug classes (EXSCEL: exenatide/GLP-1 RA, SUGAR-DM-HF: empagliflozin/SGLT2i, PRADA: epirubicin/anthracycline, and AMPLE: abatacept/immunomodulator and adalimumab/TNF inhibitor), we hypothesized that previously validated proteomic measures for cardiometabolic outcomes could enable the detection of beneficial and adverse drug effects in fewer participants over a shorter follow-up period. Changes in SomaSignal proteomic tests over time in response to treatment were assessed in the EXSCEL (baseline vs 1 year; once-weekly exenatide (EQW) (n) = 1812 vs control (n) = 1787), SUGAR-DM-HF (baseline vs 12 weeks and 36 weeks; empagliflozin (n) = 45 vs control (n) = 52), AMPLE (baseline vs 85 days and 1 year; abatacept (n) = 210, adalimumab (n) = 222), and PRADA (baseline vs 7-10 days and 3 months, n = 120) trial.

Clinical effectiveness, safety, and viral mutagenicity of oral favipiravir for COVID-19: results from a community-based, open-label, randomized Phase III trial.

Early community treatment of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection may reduce severe coronavirus disease (COVID-19) incidence. We evaluated clinical effectiveness, safety, and SARS-CoV-2 mutagenicity of favipiravir, an oral viral RNA polymerase inhibitor. We performed an open-label, community-based, randomized Phase III trial, recruiting non-hospitalized adults with mild COVID-19 (WHO ordinal severity score [OSS] ≤ 3).

Cardiovascular Prevention and Rehabilitation for Ischaemic Non-Obstructive Coronary Artery Disease: Implementation Considerations From a Survey of UK Health Professionals.

Aims: Investigate if UK healthcare professionals have the resources and knowledge to provide cardiovascular prevention and rehabilitation to people with ischaemic non-obstructive coronary artery disease (INOCA), and explore what type of care healthcare professionals believe patients should receive.

Design: Electronic cross-sectional survey of UK healthcare professionals, circulated between 7 January and 7 March 2022.

Methods: Quantitative data were analysed descriptively.

Supersaturated oxygen therapy using radial artery access to prevent left ventricular remodeling after anterior ST-segment elevation myocardial infarction: a randomized, controlled trial.

Background: Novel strategies to limit the size of infarction and prevent adverse remodeling and heart failure in patients following acute ST-segment elevation myocardial infarction (STEMI) are lacking. Supersaturated oxygen (SSO) therapy is approved for patients presenting within 6 h of onset of anterior STEMI using femoral artery access. The feasibility of SSO therapy via radial access is unknown.

Revascularization Strategies in ST-Segment Elevation Myocardial Infarction With Multivessel Disease: Temporal Trends, Patient Profiles, and Outcomes.

Background: Randomized trials support angiographic and physiology-guided complete revascularization (CR) vs incomplete revascularization (IR) in ST-segment elevation myocardial infarction (STEMI) with multivessel disease (MVD). The implementation of these strategies in clinical practice is uncertain.

Objectives: In patients undergoing percutaneous coronary intervention for STEMI with MVD, we assessed temporal trends in the utilization of different revascularization strategies and associated outcomes.

Prognostic Value of Microvascular Function in Takotsubo Syndrome: A Pooled Analysis of Individual Patient Data.

Background: Coronary microvascular dysfunction appears to play a major role in the pathogenesis of Takotsubo syndrome (TTS). However, the prognostic value of microvascular function measured in the acute phase of TTS is unclear.

Objectives: This study sought to assess the prognostic value of microvascular function measured invasively in the acute phase of TTS.

Design and rationale of "a pragmatic approach to the investigation of stable chest pain: A UK, multicenter, randomized trial to assess patient outcomes, quality of life and cost effectiveness (CE-MARC 3)".

Rationale: The optimal noninvasive diagnostic imaging strategy for patients with suspected coronary artery disease (CAD) is widely debated. Computed Tomography Coronary Angiography (CTCA) and functional imaging are both guideline-recommended, although comparative effectiveness in patients with intermediate-high pretest likelihood (PTL) is limited. Primary Hypothesis: We aim to establish if a personalized investigation strategy compared to CTCA first-line for allcomers, leads to improved patient outcomes.

Health Status Outcomes After Computed Tomography or Invasive Coronary Angiography for Stable Chest Pain: A Prespecified Secondary Analysis of the DISCHARGE Randomized Clinical Trial.

Importance: The effect of computed tomography (CT) vs invasive coronary angiography (ICA) on health status outcomes is unknown.

Objective: To evaluate CT and ICA first-test strategies on quality of life (QOL) and angina.

Design, Setting, And Participants: The Diagnostic Imaging Strategies for Patients With Stable Chest Pain and Intermediate Risk of Coronary Artery Disease (DISCHARGE) randomized clinical trial, conducted between October 2015 and April 2019 in 26 European centers, followed up patients with stable chest pain and intermediate probability of coronary artery disease for a median 3.

Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis.

Background And Aims: Colchicine has emerged as a safe and inexpensive anti-inflammatory medication to target the residual risk of cardiovascular events in the secondary prevention of coronary artery disease. Two recently published randomized controlled trials (RCTs) investigating colchicine in the post-stroke and post-myocardial infarction (MI) populations warrant a re-evaluation of colchicine. New evidence was synthesized in a systematic review and meta-analysis to determine the long-term efficacy and safety of colchicine for the secondary prevention of vascular disease.

Novel Contrast-Derived Indices of Coronary Microvascular Function: Potential Clinical and Cost Benefits.

Background: Intravenous adenosine induces stable myocardial hyperemia for coronary microvascular function testing. Iodinated radiographic contrast media induce transient, submaximal hyperemia. We assessed the feasibility, diagnostic value, and potential cost-effectiveness of contrast-derived indices of microvascular function.

Clinical Outcomes of an Enhanced and Conventional Monofocal IOL in Patients with Early and Intermediate Dry Age-Related Macular Degeneration.

Purpose: To compare the performance of an enhanced and conventional monofocal IOL in eyes with early and intermediate age-related macular degeneration (AMD).

Methods: This retrospective study compared one-month postoperative outcomes of patients bilaterally implanted with TECNIS Eyhance IOL (ICB00 group) or TECNIS Monofocal IOL (ZCB00 group). All patients underwent cataract surgery with pre-existing early or intermediate dry AMD.